- Home
- BDTX vs CRBP Comparison
BDTX vs CRBP Comparison
Compare BDTX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | CRBP |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 134.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BDTX | CRBP |
|---|---|---|
| Price | $2.16 | $8.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $10.20 | ★ $45.60 |
| AVG Volume (30 Days) | ★ 607.9K | 191.4K |
| Earning Date | 03-16-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $5.35 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.20 | $4.64 |
| 52 Week High | $4.94 | $20.56 |
Technical Indicators
Market Signals| Indicator | BDTX | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 45.63 |
| Support Level | $1.93 | $7.45 |
| Resistance Level | $2.86 | $8.63 |
| Average True Range (ATR) | 0.14 | 0.68 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 38.39 | 25.00 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.